MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer — Stella

Recruiting

Back to Platinum-Resistant Fallopian Tube Carcinoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Mayo Clinic in Arizona, Scottsdale, Arizona

Key details

Phase

Early testing

Sponsor

Mayo Clinic

Enrollment target

~12 participants

Started

September 2024

Primary completion

September 2028

Age range

18 Years and older

Sex

Female only

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov